{"disease":{"id":"essential-hypertension","name":"Essential hypertension","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"verapamil-hydrochloride","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"mecamylamine","indication_name":"Moderately severe to severe essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inversine","generic_name":"MECAMYLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor; alpha3/beta2","drug_class":"Autonomic Ganglionic Blocker","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"mecamylamine-hydrochloride","indication_name":"Moderate to severe essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MECAMYLAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"alacepril","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cetapril","generic_name":"ALACEPRIL","company_name":"Par Pharm","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"fenoldopam","indication_name":"Malignant essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corlopam","generic_name":"FENOLDOPAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(1A) dopamine receptor","drug_class":"Dopaminergic Agonist","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"moxonidin","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Moxonidin","company_name":"University of Aarhus","drug_phase":"discontinued","molecular_target":"5-hydroxytryptamine receptor 1A, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tilisolol","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selecal","generic_name":"TILISOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"tilisolol","quality_score":null,"revenue":null,"mechanism":"Selecal works by blocking beta-1 adrenergic receptors in the heart, reducing heart rate and blood pressure."},{"drug_id":"moxonidine","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Moxonidin","generic_name":"MOXONIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"moxonidine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nitroprusside","indication_name":"Malignant essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sodium Nitroprusside","generic_name":"NITROPRUSSIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Vasodilator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bunazosin","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Detantol","generic_name":"BUNAZOSIN","company_name":"","drug_phase":"phase_3","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"bunazosin","quality_score":null,"revenue":null,"mechanism":"Detanidol works by blocking the alpha-1A adrenergic receptor, which helps to relax blood vessels and lower blood pressure."}],"pipeline":[{"drug_id":"chlorthalidone","indication_name":"Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":11,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT00741585","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":21983,"lead_sponsor_name":"University of Vigo","has_results":false},{"nct_id":"NCT06395194","title":"Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15313,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06130124","title":"S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Hanlim Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT03649646","title":"FimasaRtan-basEd BP Targets After Drug SwitcHing","phase":"","overall_status":"COMPLETED","enrollment_count":4542,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":true},{"nct_id":"NCT04470817","title":"A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":3438,"lead_sponsor_name":"Celltrion Pharm, Inc.","has_results":false},{"nct_id":"NCT03847350","title":"Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":3250,"lead_sponsor_name":"A.Menarini Asia-Pacific Holdings Pte Ltd","has_results":false},{"nct_id":"NCT03708601","title":"Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases","has_results":false},{"nct_id":"NCT06778239","title":"Childhood-Onset Essential Hypertension Natural History Study","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT02603809","title":"Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1659,"lead_sponsor_name":"Idorsia Pharmaceuticals Ltd.","has_results":true},{"nct_id":"NCT06604897","title":"Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1405,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT06282549","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1219,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT05947448","title":"Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1215,"lead_sponsor_name":"Hasten Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03480217","title":"Implementing Hypertension Screening Guidelines in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":1186,"lead_sponsor_name":"Columbia University","has_results":true},{"nct_id":"NCT05359068","title":"Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":957,"lead_sponsor_name":"Shanghai Pharmaceuticals Holding Co., Ltd","has_results":false},{"nct_id":"NCT05385770","title":"Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":890,"lead_sponsor_name":"Celltrion","has_results":false},{"nct_id":"NCT06716970","title":"QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":810,"lead_sponsor_name":"Wuhan Createrna Science and Technology Co., Ltd","has_results":false},{"nct_id":"NCT03371797","title":"Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"PharmEvo Pvt Ltd","has_results":false},{"nct_id":"NCT04470830","title":"A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Celltrion Pharm, Inc.","has_results":false},{"nct_id":"NCT03514641","title":"An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Theracos","has_results":true},{"nct_id":"NCT00758524","title":"A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":628,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06321159","title":"Investigation of the Effect of Mobile Software Use in Blood Pressure Management of Hypertensive Individuals on Quality of Life and Disease Self-Efficacy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":614,"lead_sponsor_name":"Inonu University","has_results":false},{"nct_id":"NCT02480764","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":612,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06771245","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":606,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT00667719","title":"A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":564,"lead_sponsor_name":"Novartis","has_results":true},{"nct_id":"NCT03945305","title":"Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Yi Yang","has_results":false},{"nct_id":"NCT06465264","title":"To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04488978","title":"Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Handok Inc.","has_results":false},{"nct_id":"NCT05880056","title":"Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":406,"lead_sponsor_name":"Genuine Research Center, Egypt","has_results":false},{"nct_id":"NCT02517866","title":"Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06500689","title":"To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05931224","title":"Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":346,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT02277691","title":"A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":341,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07373613","title":"A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":330,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06643819","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":324,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT06091176","title":"Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension","phase":"NA","overall_status":"UNKNOWN","enrollment_count":316,"lead_sponsor_name":"Newel Health SRL","has_results":false},{"nct_id":"NCT05503953","title":"Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":306,"lead_sponsor_name":"Ahn-Gook Pharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT06501651","title":"Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":297,"lead_sponsor_name":"Sichuan Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06608472","title":"Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":292,"lead_sponsor_name":"Eurofarma Laboratorios S.A.","has_results":false},{"nct_id":"NCT07116863","title":"A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"Kyungdong Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05476354","title":"Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":271,"lead_sponsor_name":"Handok Inc.","has_results":false},{"nct_id":"NCT03991442","title":"BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":257,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06212648","title":"Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"Shin Poong Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT05878561","title":"A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03246555","title":"Fimasartan in the Senior Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06121518","title":"Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT03924115","title":"Evaluation of a Transmedial Psychoeducational Program to Improve Pharmacological Adherence","phase":"NA","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"Universidad de Concepcion","has_results":false},{"nct_id":"NCT07051811","title":"To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension","phase":"NA","overall_status":"RECRUITING","enrollment_count":213,"lead_sponsor_name":"Lepu Medical Technology (Beijing) Co., Ltd.","has_results":false},{"nct_id":"NCT02839382","title":"The Northwest Coalition for Primary Care Practice Support","phase":"NA","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT04306627","title":"Effect of Atorvastatin on Carotid Intima Media Thickness","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Yerevan State Medical University","has_results":false},{"nct_id":"NCT06041529","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":198,"lead_sponsor_name":"Yuhan Corporation","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}